vaccine, ZyCoV-D, an official told Mint. “The ZyCoV-D vaccine has been recommended for approval on Thursday during the meeting," the official said.
The drugmaker has also evaluated a two-dose regimen for ZyCoV-D vaccine using a 3 mg dose per visit and the immunogenicity results had been found to be equivalent to the current three-dose regimen. "We have also asked the company to submit additional data for the 2-dose regimen of its vaccine," the official said.
The SEC is, however, evaluating the data already submitted by the company and is likely to give final approval. The Ahmedabad-based pharmaceutical firm had applied to the Drug Controller General of India (DCGI) for EUA for its three-dose ZyCoV-D, its plasmid DNA vaccine against